Vasoactive intestinal polypeptide induces analgesia and impairs the antinociceptive effect of morphine in mice

M. Mácsai, G. Szabó, G. Telegdy

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vasoactive intestinal polypeptide (VIP) has numerous regulatory roles in peripheral, endocrine organs and in the central nervous system. The present study related to the effects of centrally (intracerebroventricularly) administered VIP on pain sensitivity and on opiate tolerance and dependence in intact male CFLP mice. VIP was analgesic when administered alone centrally. Naloxone treatment abolished this analgesic effect. VIP decreased the analgesic effect of a single subcutaneous morphine injection and the development of chronic tolerance to morphine. Morphine withdrawal signs were not significantly affected after VIP pretreatment. These findings indicate that VIP may play a role in pain sensitivity and that an opiate component may participate in this effect.

Original languageEnglish
Pages (from-to)557-562
Number of pages6
JournalNeuropeptides
Volume32
Issue number6
DOIs
Publication statusPublished - 1998

Fingerprint

Vasoactive Intestinal Peptide
Analgesia
Morphine
Opiate Alkaloids
Analgesics
Opioid-Related Disorders
Pain
Neurology
Subcutaneous Injections
Naloxone
Central Nervous System

ASJC Scopus subject areas

  • Endocrinology
  • Clinical Neurology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Neuroscience(all)
  • Biochemistry

Cite this

Vasoactive intestinal polypeptide induces analgesia and impairs the antinociceptive effect of morphine in mice. / Mácsai, M.; Szabó, G.; Telegdy, G.

In: Neuropeptides, Vol. 32, No. 6, 1998, p. 557-562.

Research output: Contribution to journalArticle

@article{115534cccaf44d5d9f73af0028c5f8b9,
title = "Vasoactive intestinal polypeptide induces analgesia and impairs the antinociceptive effect of morphine in mice",
abstract = "Vasoactive intestinal polypeptide (VIP) has numerous regulatory roles in peripheral, endocrine organs and in the central nervous system. The present study related to the effects of centrally (intracerebroventricularly) administered VIP on pain sensitivity and on opiate tolerance and dependence in intact male CFLP mice. VIP was analgesic when administered alone centrally. Naloxone treatment abolished this analgesic effect. VIP decreased the analgesic effect of a single subcutaneous morphine injection and the development of chronic tolerance to morphine. Morphine withdrawal signs were not significantly affected after VIP pretreatment. These findings indicate that VIP may play a role in pain sensitivity and that an opiate component may participate in this effect.",
author = "M. M{\'a}csai and G. Szab{\'o} and G. Telegdy",
year = "1998",
doi = "10.1016/S0143-4179(98)90085-3",
language = "English",
volume = "32",
pages = "557--562",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Vasoactive intestinal polypeptide induces analgesia and impairs the antinociceptive effect of morphine in mice

AU - Mácsai, M.

AU - Szabó, G.

AU - Telegdy, G.

PY - 1998

Y1 - 1998

N2 - Vasoactive intestinal polypeptide (VIP) has numerous regulatory roles in peripheral, endocrine organs and in the central nervous system. The present study related to the effects of centrally (intracerebroventricularly) administered VIP on pain sensitivity and on opiate tolerance and dependence in intact male CFLP mice. VIP was analgesic when administered alone centrally. Naloxone treatment abolished this analgesic effect. VIP decreased the analgesic effect of a single subcutaneous morphine injection and the development of chronic tolerance to morphine. Morphine withdrawal signs were not significantly affected after VIP pretreatment. These findings indicate that VIP may play a role in pain sensitivity and that an opiate component may participate in this effect.

AB - Vasoactive intestinal polypeptide (VIP) has numerous regulatory roles in peripheral, endocrine organs and in the central nervous system. The present study related to the effects of centrally (intracerebroventricularly) administered VIP on pain sensitivity and on opiate tolerance and dependence in intact male CFLP mice. VIP was analgesic when administered alone centrally. Naloxone treatment abolished this analgesic effect. VIP decreased the analgesic effect of a single subcutaneous morphine injection and the development of chronic tolerance to morphine. Morphine withdrawal signs were not significantly affected after VIP pretreatment. These findings indicate that VIP may play a role in pain sensitivity and that an opiate component may participate in this effect.

UR - http://www.scopus.com/inward/record.url?scp=0032421035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032421035&partnerID=8YFLogxK

U2 - 10.1016/S0143-4179(98)90085-3

DO - 10.1016/S0143-4179(98)90085-3

M3 - Article

C2 - 9920454

AN - SCOPUS:0032421035

VL - 32

SP - 557

EP - 562

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 6

ER -